The Study
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
We don't know enough about how the study was done to say if one medicine really works better than another. The title says it was a fair test, but the summary doesn't prove it, so we can't trust any claims about which drug is better.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
Two different diabetes medicines were tested: one shot once a day (liraglutide) and another shot twice a day (exenatide).
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 520 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1For people with type 2 diabetes, this means fewer shots and better blood sugar control with less risk of low blood sugar.
- 2The once-a-day shot lowered blood sugar more and caused fewer side effects than the twice-a-day shot.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Lancet
Year
2009
Authors
J. Buse, J. Rosenstock, G. Sesti, W. Schmidt, E. Montanya, J. Brett, M. Zychma, L. Blonde
Related Content
Claims (2)
GLP-1 drugs cause different amounts of weight loss in different people.
In adults with type 2 diabetes, once-daily liraglutide leads to better blood sugar control and fewer side effects than twice-daily exenatide, particularly when weight loss and low risk of low blood sugar are important.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.